{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T12:48:04Z","timestamp":1789044484852,"version":"build-2803163510"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,8]]},"abstract":"<jats:sec><jats:title>Background:<\/jats:title><jats:p>Clobazam (CLB) is approved as adjunctive treatment for seizures associated with Lennox\u2013Gastaut syndrome in patients aged 2 years and older. It is converted to an active metabolite N-desmethylclobazam (NCLB) by CYP3A4, which is then broken down to an inactive metabolite by CYP2C19. This study characterizes the impact of CYP3A4 and CYP2C19 drug interactions on CLB and NCLB serum concentrations (Cp) and concentration\/dose (Cp\/D) ratios in pediatric patients with epilepsy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p>This was a retrospective chart review including patients older than 1 month, who received CLB between April 2012 and March 2017. Extracted data included patient demographics, CLB daily dose, CLB and NCLB Cp, calculated CLB and NCLB Cp\/Cp and Cp\/D ratios, and all concomitant drugs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>The study included 995 CLB concentration sets from 302 patients (median age 7.6 years and range 0.2\u201340.1 years). Pharmacokinetic variability was extensive, as seen by widespread ranges of CLB and NCLB Cp, NCLB\/CLB Cp ratio, and 3 Cp\/D ratios (CLB, NCLB, and CLB + NCLB). Comedications, described as CYP3A4 inducers and\/or CYP2C19 inhibitors (carbamazepine, eslicarbazepine, felbamate, (fos)phenytoin, oxcarbazepine, pentobarbital, phenobarbital, rufinamide, and topiramate), generally increased NCLB\/CLB Cp ratio (267%\u2013400%), NCLB Cp\/D ratio (167%\u2013202%), and CLB + NCLB Cp\/D ratio (142%\u2013185%) and decreased CLB Cp\/D ratio (47%\u201376%) compared with a group of concentration sets in patients receiving only neutral comedications (<jats:italic toggle=\"yes\">P<\/jats:italic>&lt; 0.025 for all comparisons). Older age was associated with higher Cp\/D ratios (mg\/kg), indicative of decreased clearance.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions:<\/jats:title><jats:p>Pharmacokinetic variability of CLB in pediatric patients is extensive, and it is influenced by drug\u2013drug interactions and age. Therapeutic drug monitoring of CLB and active metabolite NCLB with calculation of various Cp\/Cp and Cp\/D ratios can provide useful insight into CLB pharmacokinetics and help differentiate between causes of variability.<\/jats:p><\/jats:sec>","DOI":"10.1097\/ftd.0000000000000530","type":"journal-article","created":{"date-parts":[[2018,5,10]],"date-time":"2018-05-10T02:38:02Z","timestamp":1525919882000},"page":"452-462","source":"Crossref","is-referenced-by-count":13,"title":["Impact of Drug Interactions on Clobazam and N-Desmethylclobazam Concentrations in Pediatric Patients With Epilepsy"],"prefix":"10.1097","volume":"40","author":[{"given":"Gabrielle R.","family":"Russell","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy and Translational Science, The University of Tennessee Health Science Center, Memphis, Tennessee;"},{"name":"Le Bonheur Children's Hospital, Memphis, Tennessee; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie J.","family":"Phelps","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Translational Science, The University of Tennessee Health Science Center, Memphis, Tennessee;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chasity M.","family":"Shelton","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Translational Science, The University of Tennessee Health Science Center, Memphis, Tennessee;"},{"name":"Le Bonheur Children's Hospital, Memphis, Tennessee; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James W.","family":"Wheless","sequence":"additional","affiliation":[{"name":"Le Bonheur Children's Hospital, Memphis, Tennessee; and"},{"name":"Department of Pediatric Neurology, The University of Tennessee Health Science Center, Memphis, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230814","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.nurt.2006.11.002","article-title":"Clobazam","volume":"4","author":"Ng","year":"2007","journal-title":"Neurotherapeutics."},{"key":"R3-20230814","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1124\/dmd.32.11.1279","article-title":"In vitro characterization of clobazam metabolism by recombinant cytochrome P450 enzymes: importance of CYP2C19","volume":"32","author":"Giraud","year":"2004","journal-title":"Drug Metab Dispos."},{"key":"R4-20230814","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/j.1528-1167.2008.01561.x","article-title":"Antiepileptic drugs\u2014best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies","volume":"49","author":"Patsalos","year":"2008","journal-title":"Epilepsia."},{"key":"R5-20230814","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1097\/FTD.0b013e31827ada88","article-title":"Clobazam therapeutic drug monitoring: a comprehensive review of the literature with proposals to improve future studies","volume":"35","author":"de Leon","year":"2013","journal-title":"Ther Drug Monit."},{"key":"R6-20230814","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1177\/0883073812463609","article-title":"Clobazam: a newly approved but well-established drug for the treatment of intractable epilepsy syndromes","volume":"28","author":"Wheless","year":"2013","journal-title":"J Child Neurol."},{"key":"R7-20230814","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1097\/FTD.0000000000000272","article-title":"Therapeutic drug monitoring of clobazam and its metabolite-impact of age and comedication on pharmacokinetic variability","volume":"38","author":"Burns","year":"2016","journal-title":"Ther Drug Monit."},{"key":"R8-20230814","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1002\/j.1875-9114.2012.01028.x","article-title":"Pharmacokinetic drug interactions between clobazam and drugs metabolized by cytochrome P450 isoenzymes","volume":"32","author":"Walzer","year":"2012","journal-title":"Pharmacotherapy."},{"key":"R9-20230814","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1002\/jcph.603","article-title":"Drug-metabolism mechanism: knowledge-based population pharmacokinetic approach for characterizing clobazam drug-drug interactions","volume":"56","author":"Tolbert","year":"2016","journal-title":"J Clin Pharmacol."},{"key":"R10-20230814","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1007\/s00228-014-1719-5","article-title":"Impact of cytochrome P450 inducers with or without inhibitors on the serum clobazam level in patients with antiepileptic polypharmacy","volume":"70","author":"Yamamoto","year":"2014","journal-title":"Eur J Clin Pharmacol."},{"key":"R15-20230814","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/clpt.1993.25","article-title":"A potentially hazardous interaction between erythromycin and midazolam","volume":"53","author":"Olkkola","year":"1993","journal-title":"Clin Pharmacol Ther."},{"key":"R21-20230814","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/j.1600-0773.1990.tb00799.x","article-title":"Effect of age and antiepileptic drugs on plasma levels and kinetics of clobazam and N-desmethylclobazam","volume":"67","author":"Bun","year":"1990","journal-title":"Pharmacol Toxicol."},{"key":"R22-20230814","first-page":"119","article-title":"Clobazam in drug-resistant and alcoholic withdrawal seizures","volume":"20","author":"Franceschi","year":"1983","journal-title":"Clin Trials J."},{"key":"R23-20230814","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1111\/j.1365-2125.1984.tb02558.x","article-title":"Single dose pharmacokinetic study of clobazam in normal volunteers and epileptic patients","volume":"18","author":"Jawad","year":"1984","journal-title":"Br J Clin Pharmacol."},{"key":"R24-20230814","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/S0090-9556(25)08020-1","article-title":"Analysis of parent drug- metabolite relationship in the presence of an inducer, application to the carbamazepine-clobazam interaction in normal man","volume":"11","author":"Levy","year":"1983","journal-title":"Drug Metab Dispos."},{"key":"R25-20230814","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1111\/j.1365-2125.1990.tb03699.x","article-title":"The effect of clobazam on steady state plasma concentrations of carbamazepine and its metabolites","volume":"29","author":"Munoz","year":"1990","journal-title":"Br J Clin Pharmacol."},{"key":"R26-20230814","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1097\/00007691-199208000-00002","article-title":"Interactions between clobazam and standard antiepileptic drugs in patients with epilepsy","volume":"14","author":"Sennoune","year":"1992","journal-title":"Ther Drug Monit."},{"key":"R27-20230814","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1097\/00007691-199912000-00004","article-title":"Effect of felbamate on clobazam and its metabolite kinetics in patients with epilepsy","volume":"21","author":"Contin","year":"1999","journal-title":"Ther Drug Monit."},{"key":"R28-20230814","doi-asserted-by":"crossref","first-page":"214","DOI":"10.2165\/00003088-199733030-00004","article-title":"Pharmacokinetic interactions with felbamate. In vitro-in vivo correlation","volume":"33","author":"Glue","year":"1997","journal-title":"Clin Pharmacokinet."},{"key":"R29-20230814","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1472-8206.2000.tb00411.x","article-title":"Enzyme induction and inhibition by new antiepileptic drugs: a review of human studies","volume":"14","author":"Benedetti","year":"2000","journal-title":"Fundam Clin Pharmacol."},{"key":"R32-20230814","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1046\/j.1365-2710.1998.00086.x","article-title":"Clinically important pharmacokinetic drug\u2013drug interactions: role of cytochrome P450 enzymes","volume":"23","author":"Tanaka","year":"1998","journal-title":"J Clin Pharm Ther."},{"key":"R33-20230814","first-page":"391","article-title":"The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects","volume":"76","author":"Lynch","year":"2007","journal-title":"Am Fam Physician."},{"key":"R36-20230814","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1124\/dmd.32.3.364","article-title":"Is 17 alpha-ethinyl estradiol an inhibitor of cytochrome P450 2C19?","volume":"32","author":"Rodrigues","year":"2004","journal-title":"Drug Metab Dispos."},{"key":"R37-20230814","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1177\/0091270003252519","article-title":"The conduct of in vitro and in vivo drug-drug interaction studies: a PhRMA Perspective","volume":"43","author":"Bjornsson","year":"2003","journal-title":"J Clin Pharmacol."},{"key":"R39-20230814","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.spen.2010.10.002","article-title":"Developmental pharmacokinetics","volume":"17","author":"Anderson","year":"2010","journal-title":"Semin Pediatr Neurol."},{"key":"R40-20230814","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1177\/088307389701200311","article-title":"Interactions of clobazam with conventional antiepileptics in children","volume":"12","author":"Theis","year":"1997","journal-title":"J Child Neurol."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00007691-201808000-00011","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T12:05:00Z","timestamp":1751630700000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007691-201808000-00011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000530","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]}}}